TrainParC

Cognitive training for the therapy of mild cognitive disorders (PD-MCI) of Parkinson's disease

General

The symptoms of Parkinson's disease (PD) are associated not only with the occurrence of the characteristic motor symptoms, but also with a variety of non-motor problems, especially cognitive impairment. Mild cognitive impairment (PD-MCI) in PD increases the risk of developing Parkinson's disease (PDD) in the disease course. Drug treatment to improve cognition is currently only approved for PDD patients. Treatment is therefore only possible at a time when the cognitive impairment significantly interfere with patients' everyday life. Therefore, an effective non-pharmacological therapy of cognitive disorders at the PD-MCI stage would be desirable, which stabilizes the everyday competence of PD patients in the early process of cognitive decline and thus maintains the patients' quality of life and independence in the long term.

Background and aims

The aim of this randomized controlled trial is to evaluate the extent to which a six-week cognitive training in small groups (5-8 participants) compared to a stretching training, improves the cognitive performance of PD-MCI patients in the short term and the extent to which the training prevents a further reduction in cognitive performance. Furthermore, predictors for the success of therapy as well as neuronal mechanisms are investigated by means of electroencephalogram (EEG) of possible training effects.

Overview

The TrainParC study investigates a total of 80 PD-MCI study participants who are randomized to double-blind cognitive or control training. The inclusion age is between 50 and 80 years. A follow-up measurement to assess the mid-term therapeutic success after 6 and 12 months is intended.

Course of the study

Pre-, post- and 6 and 12-monthly progression examinations include an extensive neuropsychological testing, a assessment of the motor status and information of the participants and their relatives about the functional status and the occurrence or severity of other non-motor symptoms (e. g. depression). In addition, a blood collection as well as an EEG and movement measurement is carried out in the home environment.

Principle Investigator: Priv.-Doz. Dr. Inga Liepelt-Scarfone, Prof.Dr. Elke Kalbe
Start of the study: 2016
Status: multi centric, study closed

Study Coordination / Project Management

Priv.-Doz. Dr. Inga Liepelt-Scarfone
inga.liepelt@dzne.de
 +49 7071 29-80171
 +49 7071 29-4490
M. Sc. Patricia Sulzer
patricia.sulzer@med.uni-tuebingen.de
 +49 7071 29-85790
 +49 7071 29-4490

Participating sites

Düsseldorf

in cooperation with
Universitätsklinik Düsseldorf - Neurologische Klinik
Local principle investigator: 
Dr. med. Lars Wojtecki
Local contact:
+49 211 8108472

Kiel

in cooperation with
Universitätsklinik S.-H. Campus Kiel - Neurologische Klinik
Local principle investigator: 
Prof. Dr. Karsten Witt
Local contact:
+49 431 597-8501

Cologne

in cooperation with
Universitätsklinik Köln - Medizinische Psychologie
Local principle investigator: 
Prof. Dr. Elke Kalbe
Local contact:
+49 221 478-96244
+49 221 478-6999

Tübingen

DZNE
Local principle investigator: 

Priv.-Doz. Dr. Inga Liepelt-Scarfone
Local contact:
Patricia Sulzer
+49 7071 29-85790

Info-Hotline

Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: